Also, only patients with ALK mutations are treated with ALK inhibitors in clinical trials, and ALK mutations occur in about 9% of NB; however, ALK or other RTK overactivation occurs almost in the majority of NB cases. The gene discussed is ALK; the disease is neuroblastoma.